Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics - 09/08/11
, Christopher P. Cannon, MD b, Hertzel C. Gerstein, MD, MSc c, Richard W. Nesto, MD d, Patrick W. Serruys, MD, PhD e, Gerrit-Anne van Es, PhD f, Nikheel S. Kolatkar, MD, MPH g, Barbara G. Kravitz, MS g, Andrew Zalewski, MD, PhD g, Peter J. Fitzgerald, MD, PhD hThe APPROACH study group
Résumé |
Background |
Rosiglitazone, a thiazolidinedione, has effects on insulin sensitivity and cardiovascular risk factors that may favorably impact the progression of coronary atherosclerosis.
Methods |
APPROACH is a double-blind randomized clinical trial comparing the effects of the insulin sensitizer rosiglitazone with the insulin secretagogue glipizide on the progression of coronary atherosclerosis. Patients with type 2 diabetes and coronary artery disease undergoing clinically indicated coronary angiography or percutaneous coronary intervention are randomized to receive rosiglitazone or glipizide for 18 months using a titration algorithm designed to provide comparable glycemic control between treatment groups. The primary end point is change in percent atheroma volume from baseline to study completion in a nonintervened coronary artery, as measured by intravascular ultrasound. Cardiovascular events are adjudicated by an end point committee.
Results |
A total of 672 patients were randomized. The mean age was 61 years, hemoglobin A1c (HbA1c) 7.2%, body mass index 29.5 kg/m2, and median duration of diabetes 4.8 years. At baseline, approximately half of the participants were receiving oral antidiabetic monotherapy (53.9%) with 27.5% receiving dual combination therapy and 17.9% treated with diet and exercise alone. Approximately two thirds of the participants (68%) had dyslipidemia, 79.9% hypertension, and 24% prior myocardial infarction.
Conclusions |
APPROACH has fully enrolled a high-risk patient population and will compare the glucose-independent effects of rosiglitazone and glipizide on the progression of coronary atherosclerosis, as well as provide additional data on the cardiovascular safety of rosiglitazone in patients with type 2 diabetes and coronary artery disease.
Le texte complet de cet article est disponible en PDF.Plan
| The study was supported by funds from GlaxoSmithKline, King of Prussia, PA. |
|
| ClinicalTrials.gov indentifier: NCT00116831. |
Vol 156 - N° 6
P. 1074-1079 - décembre 2008 Retour au numéro
Article précédent
- Uncontrolled immune response in acute myocardial infarction : Unraveling the thread
- Vicente Bodi, Juan Sanchis, Julio Nunez, Luis Mainar, Gema Minana, Isabel Benet, Carlos Solano, Francisco J. Chorro, Angel Llacer
- Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non–ST-elevation acute coronary syndromes managed with an early invasive strategy
- Shamir R. Mehta, Jean-Pierre Bassand, Susan Chrolavicius, Rafael Diaz, Keith A.A. Fox, Christopher B. Granger, Sanjit Jolly, Hans-Jurgen Rupprecht, Petr Widimsky, Salim Yusuf, on behalf of the CURRENT OASIS 7 Steering Committee h
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?